Segment Data

12 Months Ended

Dec. 31, 2023

Segment Data

Segment Data

14. Segment Data

The Company has two reportable segments-human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is approved by the FDA for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

The Company's reportable segments net revenues and net loss for the years ended December 31, 2023 and 2022 consisted of the following:

	Year Ended
	December 31,
(in thousands)	2023		2022
Revenue from external customers
Human Health	$	9,588	$	11,741
Animal Health		173		215
Consolidated Totals	$	9,761	$	11,956
Segment net loss
Human Health	$	(21,655)	$	(18,278)
Animal Health		(20,246)		(30,117)
Consolidated Totals	$	(41,901)	$	(48,395)

The Company’s reportable segments assets consisted of the following:

	December 31,		December 31,
	2023		2022
(in thousands)
Segment assets
Human Health	$	42,289	$	40,898
Animal Health		153,190		128,607
Total	$	195,479	$	169,505

The reconciliation of segments assets to the consolidated assets is as follows:

	December 31,		December 31,
(in thousands)	2023		2022
Total assets for reportable segments	$	195,479	$	169,505
Less: Investment in subsidiary		(29,232)		(29,232)
Less: Intercompany loan		(115,484)		(92,821)
Consolidated Totals	$	50,763	$	47,452